NASDAQ:AUTL

Autolus Therapeutics (AUTL) Stock Forecast, Price & News

$2.26

-0.07 (-3.00%)

(As of 10:20 AM ET)

Compare

Today's Range: $2.26
▼
$2.35
50-Day Range: $2.32
▼
$3.36
52-Week Range: $1.60
▼
$3.54

Volume: 38,976 shs
Average Volume: 551,423 shs
Market Capitalization: $392.52 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.80

Autolus Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 234.8% Upside
$7.80 Price Target
Short Interest: Healthy
0.93% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.43
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.97) to ($0.86) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

Medical Sector

348th out of 968 stocks

Biological Products, Except Diagnostic Industry

54th out of 161 stocks

3.5

Analyst's Opinion

Consensus Rating
Autolus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $7.80, Autolus Therapeutics has a forecasted upside of 234.8% from its current price of $2.33.
Amount of Analyst Coverage
Autolus Therapeutics has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.93% of the outstanding shares of Autolus Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Autolus Therapeutics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Autolus Therapeutics has recently increased by 17.52%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Autolus Therapeutics does not currently pay a dividend.
Dividend Growth
Autolus Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AUTL.

2.5

News and Social Media Coverage

News Sentiment
Autolus Therapeutics has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Autolus Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for AUTL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
2 people have added Autolus Therapeutics to their MarketBeat watchlist in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Autolus Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
25.70% of the stock of Autolus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
64.78% of the stock of Autolus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Autolus Therapeutics are expected to grow in the coming year, from ($0.97) to ($0.86) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Autolus Therapeutics is -1.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Autolus Therapeutics is -1.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Autolus Therapeutics has a P/B Ratio of 1.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Autolus Therapeutics (NASDAQ:AUTL) Stock

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

AUTL Price History

30 days | 90 days | 365 days | Advanced Chart

AUTL Stock News Headlines

September 11, 2023 | seekingalpha.com

Autolus: CAR-T Therapy Looks Promising

September 10, 2023 | seekingalpha.com

Autolus Therapeutics: Innovating T Cell Cancer Treatments

October 2, 2023 | Edge On The Street (Ad)

Gold Could Be Heading for Record Highs - But How to Play It?

According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.

September 5, 2023 | finance.yahoo.com

Autolus Therapeutics announces data from AUTO1/22 trial in pediatric Acute Lymphoblastic Leukemia published in the journal Blood

August 23, 2023 | fool.com

Autolus Therapeutics Plc (NASDAQ: AUTL)

August 7, 2023 | insidermonkey.com

Autolus Therapeutics plc (NASDAQ:AUTL) Q2 2023 Earnings Call Transcript

August 4, 2023 | finance.yahoo.com

Autolus Therapeutics (NASDAQ:AUTL) Is In A Good Position To Deliver On Growth Plans

August 4, 2023 | seekingalpha.com

Autolus Therapeutics plc 2023 Q2 - Results - Earnings Call Presentation

October 2, 2023 | Edge On The Street (Ad)

Gold Could Be Heading for Record Highs - But How to Play It?

August 3, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Autolus Therapeutics (AUTL), Intercept Pharma (ICPT)

August 3, 2023 | msn.com

Autolus Therapeutics GAAP EPS of -$0.26 misses by $0.03

August 3, 2023 | finance.yahoo.com

Autolus Therapeutics Reports Second Quarter 2023 Financial Results and Operational Progress

July 28, 2023 | msn.com

European Equities Traded in the US as American Depositary Receipts Friday

July 19, 2023 | markets.businessinsider.com

Autolus Therapeutics Appoints Robert Dolski CFO

July 18, 2023 | finance.yahoo.com

Autolus Therapeutics to report second quarter 2023 financial results and host conference call on August 3, 2023

July 6, 2023 | finance.yahoo.com

Autolus Therapeutics announces a publication in Nature Medicine on obe-cel in Pediatric Acute Lymphoblastic Leukemia

June 30, 2023 | seekingalpha.com

Autolus Therapeutics Could Hold A Winning CAR T-Cell Ticket

June 27, 2023 | finance.yahoo.com

Autolus Therapeutics announces publication in Cancer Immunology Research

June 20, 2023 | finance.yahoo.com

Autolus Therapeutics strengthens its Board with the appointment of Dr. Robert Iannone as a Non-Executive Director

June 16, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Autolus Therapeutics (AUTL) and Anixa Biosciences (ANIX)

June 16, 2023 | finance.yahoo.com

Autolus Therapeutics Presents Positive Results from AUTO4 in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma

June 6, 2023 | finance.yahoo.com

Autolus to hold Annual General Meeting (AGM) of Shareholders on Friday, June 30, 2023

June 2, 2023 | markets.businessinsider.com

Needham Sticks to Their Buy Rating for Autolus Therapeutics (AUTL)

June 2, 2023 | markets.businessinsider.com

Where Autolus Therapeutics Stands With Analysts

May 12, 2023 | finance.yahoo.com

Autolus Therapeutics announces Pivotal Phase 2 FELIX study of obe-cel in adult r/r B-ALL selected for an oral presentation at EHA

May 7, 2023 | seekingalpha.com

Autolus Therapeutics plc 2023 Q1 - Results - Earnings Call Presentation

May 6, 2023 | msn.com

Wells Fargo Maintains Autolus Therapeutics plc - ADR (AUTL) Overweight Recommendation

See More Headlines

Receive AUTL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Autolus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AUTL Company Calendar

Last Earnings: 8/03/2023
Today: 10/02/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AUTL
CUSIP: N/A
CIK: 1730463
Web: www.autolus.com
Phone: 442038296230
Fax: N/A
Employees: 399
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $7.80
High Stock Price Forecast: $12.00
Low Stock Price Forecast: $5.00
Forecasted Upside/Downside: +240.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.19)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-148,840,000.00
Net Margins: N/A
Pretax Margin: -2,321.52%
Return on Equity: -64.88%
Return on Assets: -37.26%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.65
Quick Ratio: 8.65

Sales & Book Value

Annual Sales: $6.36 million
Price / Sales: 62.54
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.73 per share
Price / Book: 1.32

Miscellaneous

Outstanding Shares: 173,680,000
Free Float: 129,045,000
Market Cap: $397.73 million
Optionable: Not Optionable
Beta: 1.54

10 Best Stocks to Own in 2023

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Christian Martin Itin Ph.D. (Age 59)
CEO & Director
Comp: $2.68M

Dr. Martin Pule M.D. (Age 51)
MBBS, Founder, Sr. VP & Chief Scientific Officer

Mr. Christopher Vann (Age 58)
Sr. VP & COO

Mr. David Brochu (Age 67)
Sr. VP & Chief Technical Officer

Mr. Brent Rice (Age 57)
Sr. VP, Chief Commercial Officer & Site Head of US

Dr. Edgar E. W. Braendle M.D. (Age 63)
Ph.D., Sr. VP & Chief Devel. Officer

Mr. Robert F. Dolski (Age 53)
Chief Financial Officer

Ms. Olivia Manser
Director of Investor Relations

Dr. Chris Williams (Age 43)
Sr. VP of Corp. Devel.

Mr. Alexander Swan
Chief HR Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

AUTL Stock - Frequently Asked Questions

Should I buy or sell Autolus Therapeutics stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Autolus Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AUTL shares.
View AUTL analyst ratings or view top-rated stocks.
What is Autolus Therapeutics' stock price forecast for 2023?: 5 brokers have issued twelve-month target prices for Autolus Therapeutics' shares. Their AUTL share price forecasts range from $5.00 to $12.00. On average, they expect the company's stock price to reach $7.80 in the next twelve months. This suggests a possible upside of 240.6% from the stock's current price.
View analysts price targets for AUTL or view top-rated stocks among Wall Street analysts.
How have AUTL shares performed in 2023?: Autolus Therapeutics' stock was trading at $1.90 at the beginning of the year. Since then, AUTL shares have increased by 20.5% and is now trading at $2.29.
View the best growth stocks for 2023 here.
Are investors shorting Autolus Therapeutics?: Autolus Therapeutics saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 1,610,000 shares, an increase of 17.5% from the August 31st total of 1,370,000 shares. Based on an average daily volume of 441,500 shares, the short-interest ratio is presently 3.6 days.
View Autolus Therapeutics' Short Interest.
When is Autolus Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our AUTL earnings forecast.
How were Autolus Therapeutics' earnings last quarter?: Autolus Therapeutics plc (NASDAQ:AUTL) posted its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.04.
What ETF holds Autolus Therapeutics' stock ?: Range Cancer Therapeutics ETF holds 44,025 shares of AUTL stock, representing 1.33% of its portfolio.

What other stocks do shareholders of Autolus Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Autolus Therapeutics investors own include Sorrento Therapeutics (SRNE), CRISPR Therapeutics (CRSP), VBI Vaccines (VBIV), GW Pharmaceuticals (GWPH), ImmunoGen (IMGN), Teva Pharmaceutical Industries (TEVA), TG Therapeutics (TGTX), AbbVie (ABBV), Adaptimmune Therapeutics (ADAP) and Advanced Micro Devices (AMD).
When did Autolus Therapeutics IPO?: (AUTL) raised $125 million in an initial public offering on Friday, June 22nd 2018. The company issued 7,800,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers.
What is Autolus Therapeutics' stock symbol?: Autolus Therapeutics trades on the NASDAQ under the ticker symbol "AUTL."
How do I buy shares of Autolus Therapeutics?: Shares of AUTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Autolus Therapeutics' stock price today?: One share of AUTL stock can currently be purchased for approximately $2.29.
How much money does Autolus Therapeutics make?: Autolus Therapeutics (NASDAQ:AUTL) has a market capitalization of $397.73 million and generates $6.36 million in revenue each year. The company earns $-148,840,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis.
How many employees does Autolus Therapeutics have?: The company employs 399 workers across the globe.
How can I contact Autolus Therapeutics?: Autolus Therapeutics' mailing address is FOREST HOUSE 58 WOOD LANE WHITE CITY, LONDON X0, W12 7RZ. The official website for the company is www.autolus.com. The company can be reached via phone at 442038296230 or via email at ir@autolus.com.

This page (NASDAQ:AUTL) was last updated on 10/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial